Andy Holt

Chief Commercial Officer • Cellistic

Andy Holt brings more than fifteen years of experience in cell and gene therapy to Cellistic. In his prior roles, he held business development, corporate development and management positions for CDMOs, driving commercial strategy and growth in adeno-associated virus (AAV) gene therapy manufacturing. In his role at Cellistic, Andy leverages his experience in scaling up cell and gene therapy platforms to help Cellistic clients reach their goals in allogeneic cell therapy.

Also Speaking

Sharon Hesterlee

Executive Vice President, Chief Research Officer • Muscular Dystrophy Association USA

Peter Walters

Fellow, Advanced Therapies • CRB

Alex Bloom

Chief Technology Officer • AviadoBio

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.